Status:

UNKNOWN

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

Lead Sponsor:

Feng Jinzhou

Conditions:

Neuromyelitis Optica Spectrum Disorders

Eligibility:

All Genders

18+ years

Brief Summary

To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.

Detailed Description

Inebilizumab is a humanized anti-CD19 monoclonal antibody. CD19 is broadly expressed on B-lineage cells, particularly late-stage memory B-lymphocytes and plasma blasts. Inebilizumab depletes antibody-...

Eligibility Criteria

Inclusion

  • 1\. Age ≥ 18 years with anti-AQP4-IgG seropositive NMOSD as defined by 2015 NMOSD diagnostic criteria by IPND (International Panel for NMO Diagnosis).
  • 2\. Expanded disability status scale (EDSS) score ≤ 8 and ≥ 2.5 during the acute phase.
  • 3\. Patients have given their written informed consent.

Exclusion

  • 1\. Lactating and pregnant females.
  • 2\. Participate in other interventional studies within 30 days or within 5 half-lives of the investigational agent before received inebilizumab and rituximab (RTX).
  • 3\. Receipt of any experimental B-cell depleting agent within 6 months prior inebilizumab and RTX, and B-cells below the lower limit of normal
  • 4\. Known history of a severe allergy or reaction to any component of the investigational product formulation.
  • 5\. Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization (including viral hepatitis, active tuberculosis or positive tuberculosis screening).
  • 6\. History of alcohol, drug, or chemical abuse, or a recent history of such abuse \< 1 year prior to treatment.
  • 7\. History of malignancies.
  • 8\. Combined with severe mental disorders and other conditions and unable to cooperate with follow-up.

Key Trial Info

Start Date :

October 20 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2025

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT06068829

Start Date

October 20 2023

End Date

June 30 2025

Last Update

October 5 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.